Document:

Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.14  

 
 

RELEASE    
  

    KNOW AL MEN BY THESE PRESENTS that in consideration of one (US$1.00) dollar and the total payment of 71,429 shares (the "Shares") in
the capital stock of Phage Therapeutics International Inc. ("PTXX) and 85,714 share purchase warrants (the "Warrant") for the purchase of one further common share of PTXX, expiring on March 25,
2001, at the price of US$1.25 per share as described in the warrant terms and conditions attached hereto to Hornbolwer & Weeks Financial Corporation and Hornblower & Weeks Incorporated  (collectively, the
"Releasors") (the receipt of all which is hereby acknowledged), the Releasors DO HEREBY REMISE RELEASE AND FOREVER DISCHARGE Phage
Therapeutics, Inc., PTXX and any of their successors and assigns, directors, officers, employees, or agents (collectively, the "Releasees") of and from any and all
manner of actions, causes of actions, suits, debts, contracts, claims, demands, damages and obligations to pay anything (including without limitations, money, expense allowances, sales commissions,
shares of warrants) of any nature of kind whatsoever which any of the Releasors have or at any time hereafter can, shall or may have, for or by reason of, or arising out of any cause, matter or thing
whatsoever occurring or existing up to and inclusive of the date of these presents and in particular, but DO HEREBY REMISE, RELEASE AND FOREVER DISCHARGE the Releasees of and from any claims and
demands of any nature of kind whatsoever which any of the Releasors now have or at any time hereafter can, shall or may have, for or by reason of, or arising out of any agreements, whether written or
verbal, between any of the Releasors and Releasees in respect of the financing of Phage Therapeutics, Inc., including without a limitation, an investment banking
agreement made February 2, 1998 and engagement letters dated February 2, 1998 and February 10, 1998.

    AND
IT IS UNDERSTOOD AND AGREED that the Releasors will neither jointly or separately make any claim or claims or take any proceedings against any person, corporation, partnership or
partly might result in a claim for contribution or indemnity from any of the Releases and if any of the Releasors make such a claim or take such proceedings then each of the Releasors jointly and
separately covenants and agrees to save harmless and indemnify each of the Releases of any from any and all liabilities, damages, interest, costs (including legal fees and disbursements as between
legal counsel and own client), expenses and compensation of whatsoever kind in respect of any such claim for contribution and indemnify or otherwise. 

    IT
IS FURTHER UNDERSTOOD AND AGREED That this is a compromise settlement of a disputed claim and that the consideration for this Release shall not be deemed to be or be construed as
an admission of liability by the Releasees to the undersigned. 

    The
Releasors have consulted with and been advised by their legal counsel before entering into the settlement herein contained and the board of directors thereof have duly considered
and authorized the execution of this Release by way of resolutions attached hereto and warrants that the signatory hereto is of full capacity and has the authority to execute and deliver this Release,
and that the Releasors have not been influenced to any extent whatsoever in making this Release by any representations or statements regarding the said loss or damaged or regarding any other matters
made by any of the parties who will be released or by any person or persons representing the parties who will be released. Further, the Releasors understand and agree that no
representations, warranties or covenants are being made as to (1) the past, present or future value of the Shares, the Warrants or the shares which are issued as a result of the exercise of the
Warrants, or (2) PTXX, Phage Therapeutics, Inc., or tlie-busmess or as to the future viability of PTXX and Phage Therapeutics, Inc. According, the
Releasors waive their right to make any claim against the Releases. 

    IN
WITNESS WHEREOF the Releasors have duly executed this Release on August 16, 1999. 

 

HORNBLOWER & WEEKS FINANCIAL CORPORATION  

	/s/ Eric Ellenhorn
	 	 
	Per: Authorized Signatory	 	 
	Name:	 	 
	
HORNBLOWER & WEEKS INCORPORATED	
 	

 
	

/s/ Eric Ellenhorn
	
 	

 
	Per: Authorized Signatory	 	 
	Name:	 	 

    Subscribed
and sworn to me this 24th day of August, 1999 

	/s/ Barry M. Ferrari
 Notary Public	 	 

Barry
M. Ferrari

Notary Public, State of New York

No. 01FE5070335

Qualified in Orange County

Commission Expires December 9, 2000

 
 

RELEASE    
  

    KNOW AL MEN BY THESE PRESENTS that in consideration of one (US$I.00) dollar to Phage Therapeutics Inc., (the
"Releasor") (the receipt of which is hereby acknowledged), Phage Therapeutics, Inc. DOES HEREBY REMISE, RELEASE AND FOREVER DISCHARGE  Hornblower & Weeks Financial
Corporation and Hornblower Weeks Incorporated (collectively, the "Releasees") of and from any and all manner of
actions, causes of actions, suits, debts, contracts, claims, demands, damages of any nature or kind whatsoever which the Releasor has or at any time hereafter can, shall or may have, for or by reason
of, or arising out of any cause, matter or thing whatsoever occurring or existing up to and inclusive of the date of these presents and in particular, but without limiting the generality of the
foregoing, the Releasor DOES HEREBY REMISE, RELEASE AND FOREVER DISCHARGE the Releasees of and from any claims and demands of any nature or kind whatsoever which any of the Releasors has or at any
time hereafter can, shall or may have, for or by reason of, or arising out of any agreements, whether written or verbal, between any of the Releasor and Releasee in respect of
the financing of Phage Therapeutics, Inc., including without a limitation, an investment banking agreement made February 2, 1998 and engagement letters dated February 2, 1998 and
February 10, 1998.

    AND
IT IS UNDERSTOOD AND AGREED that the Releasors will not make any claim or claims or take any proceedings against any person, corporation, partnership or party might result in a
claim for contribution or indemnity from any of the Releasees and if the Releasor make such a claim or take such proceedings then each of the Releasor covenants and agrees to save harmless and
indemnify each of the Releasees of any from any and all liabilities, damages, interest, costs (including legal fees and disbursements as between legal counsel and own client), expenses and
compensation of whatsoever kind in respect of any such claim for contribution and indemnify or otherwise. 

    IT
IS FURTHER UNDERSTOOD AND AGREED that this is a compromise settlement of a disputed claim and that the consideration for this Release shall not be deemed to be or be construed as
an admission of liability by the Releasees to the undersigned. 

2

 

    The Releasor has consulted with and been advised by their legal counsel before entering into the settlement herein contained and the board of directors thereof have duly considered
and authorized the execution of this Release by way of resolutions attached hereto and warrants that the signatory hereto is of full capacity and has the authority to execute and deliver this Release,
and that the Releasor have not been influenced to any extent whatsoever in making this Release by any representations or statements regarding the said loss or damaged or regarding any other matters
made by any of the parties who will be released or by any person or persons representing the parties who will be released. Accordingly, the Releasor waives its rights to make any claim against the
Releasees. 

    IN
WITNESS WHEREOF the Releasors have duly executed this Release on August 16, 1999. 

PHAGE THERAPEUTICS, INC.  

	/s/ Darren Pylot
	 	 	 	 
	Per: Authorized Signatory	 	 	 	 
	Name: Darren Pylot, Director	 	 	 	 

3

QuickLinks

RELEASE

RELEASEPrepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.15  

 
 

STOCK PURCHASE AGREEMENT    
  

    This Stock Purchase Agreement ("Agreement") is dated as of May 1, 2001 between Phage Therapeutics International, Inc., a Florida corporation
("Phage International");            ("Vendor"); and            ("Purchaser"). 

RECITALS  

    A.  Pursuant
to a Purchase Agreement dated April 20, 1999 (the "Purchase Agreement"), Vendor agreed to sell to Phage International all of Vendor's shares of
Phage Therapeutics, Inc., a Washington corporation ("Phage"), in exchange for            newly-issued shares (the "Phage International Shares") of Phage International (the "Initial
Transaction"). 

    B.  Vendor
delivered the executed Purchase Agreement, but not all of the other documents necessary to close the Initial Transaction, to Phage International in August,
1999. As a result, Phage International did not issue to Vendor a certificate representing the Phage International Shares. 

    C.  Purchaser
desires to purchase the Phage International Shares from Vendor. The parties desire to enter into this Agreement to set forth certain agreements with
respect to these transactions. 

AGREEMENTS  

    In exchange for the mutual promises and covenants contained in this Agreement, the panties agree as follows: 

    1.  Initial Transaction.  The parties believe that Vendor delivered the Purchase Agreement to Phage
International by August 31, 1999. Certain of the closing documents specified in Article 8.1(a) of the Purchase Agreement were not initially delivered to Phage International with
that document, however, and accordingly the certificates representing the Phage International Shares were not previously issued by Phage International. Subject to delivery of all documents necessary
to conclude the transactions contemplated by this Agreement, Vendor and Phage International agree to adopt August 31, 1999 as the date of Vendor's acquisition of the shares. 

    2.  Purchase by Purchaser.  Vendor hereby sells to Purchaser, and Purchaser purchases from Vendor, all of
Vendor's right, title and interest in and to the Phage International Shares, for a price of $1.00 per share, for a total purchase price of $150,000. Purchaser shall pay the purchase price to Vendor as
follows: (i) promptly upon the execution and delivery of this Agreement by all parties, Purchaser shall pay Vendor an amount equal to 10% of the total purchase price; and (ii) Purchaser
shall pay the balance of the purchase price when (a) Vendor has delivered to Phage International all documents Stock Purchase Agreement page required by the Purchase Agreement and any stock
certificates, stock powers, incumbency certificates, and other documents required by Phage International or its transfer agent in order to conclude the transactions contemplated by this Agreement and
(b) the transfer agent has confirmed that it is prepared to issue a certificate representing the Phage International Shares to Purchaser. In lieu of the issuance of a certificate representing
the Phage International Shares to Vendor, and the subsequent assignment of that certificate to Purchaser, Vendor and Purchaser instruct Phage International to issue a certificate representing the
Phage International Shares directly to Purchaser. 

    3.  Representations and Warranties of Vendor.  Vendor represents and warrants to Phage International and
Purchaser as follows: 

    3.1 Vendor
has good and marketable title to the Phage International Shares, has full power and authority to transfer such shares, and this Agreement constitutes the
valid and binding 

1

 

obligation of Vendor enforceable in accordance with its terms. The Phage International Shares have not been pledged or encumbered in any manner, and are not subject to any claim of beneficial
ownership by any person other than Vendor. Upon transfer of the Phage International Shares to Purchaser pursuant to this Agreement, Purchaser will acquire title to such shares, free and clear of all
liens, claims, or encumbrances of any kind. 

    3.2 The
representations and warranties made by Vendor in the Purchase Agreement were true and correct when made, and Vendor restates such representations and warranties
as of the date of this Agreement. 

    3.3 At
the time of the Purchase Agreement and since then, Vendor has been given the opportunity to ask questions of, and to receive answers from, Phage International's
senior management, and to obtain any additional information requested, concerning Phage International and the Phage International Shares, to the extent desired by Vendor. 

    3.4 Vendor
is and, since April of 1999, has been an "Accredited Investor" as that term is defined under Regulation D promulgated by the Securities and Exchange
Commission. 

    3.5 Vendor
has received and reviewed a copy of Phage International's Form 10-SB initially filed with the Securities and Exchange Commission on December 7, 2000
and subsequently amended (the "Form 10-SB"). Vendor acknowledges that, except as set forth in the Form 10-SB, neither Phage International nor Purchaser has made any representations to Vendor regarding
the business affairs, operations, financial condition or prospects of Phage and Phage International. 

    3.6 The
Phage International Shares were acquired by Vendor in good faith solely for the Vendor's personal account, for investment purposes only, and were not purchased
with a view to or for the resale, distribution, transfer, subdivision or fractionalization thereof. 

    3.7 Vendor
has had the opportunity to consult with its legal, financial and tax advisors with respect to this investment, to the extent desired by Vendor. 

    4.  Representations and Warranties of Purchaser.  Purchaser represents and warrants to Phage
International and Vendor as follows: 

    4.1 Purchaser
has been given the opportunity to ask questions of, and to receive answers from, Phage International's senior management, and to obtain any additional
information requested, concerning Phage International and the Phage International Shares, to the extent desired by Purchaser. Purchaser is fully aware of the business affairs, operations, financial
condition and prospects of Phage and Phage International. 

    4.2 Purchaser
is an "Accredited Investor" as that term is defined under Regulation D promulgated by the Securities and Exchange Commission. Purchaser's other
investments, financial situation, and needs
are such that it is able (i) to bear the economic risk of this investment; (ii) to hold the Phage International Shares for an indefinite period of time; and (iii) to afford a
complete loss of this investment. 

    4.3 Purchaser
has received and reviewed a copy of the Form 10-SB. Purchaser acknowledges that the Phage International Shares will not be registered by virtue of the
filing of the Form 10-SB. Purchaser has no need for liquidity in this investment and understands that there are substantial restrictions on the transferability of the Phage International Shares, and
that, accordingly, it may not be possible to liquidate an investment in the Phage International Shares when desired or needed by Purchaser. Purchaser has read and is familiar with the requirements of
Rule 144 promulgated under the Securities Act of 1933. 

    4.4 Purchaser
understands that the Phage International Shares were offered and sold under exemptions from registration provided for under federal and state securities
laws, and that the 

2

 

Phage International Shares may not be sold or transferred without registration or the availability of an exemption from registration under such laws. Purchaser understands that Phage International has
no obligation or current intention to register the Phage International Shares at any time in the future. 

    4.5 Purchaser
understands that it will not be entitled to any guaranteed dividend, interest or fixed return on this investment, and that Phage International is under no
obligation to redeem any or all of the Phage International Shares at any time in the future. 

    4.6 The
Phage International Shares are being acquired in good faith solely for the personal account of Purchaser, for investment purposes only, and are not being
purchased with a view to or for the resale, distribution, transfer, subdivision or fractionalization thereof. 

    4.7 Purchaser
has had the opportunity to consult with its legal, financial and tax advisors with respect to this investment, to the extent it desires. 

    5.  Stock Certificates and Restrictive Legend.  When the conditions to full payment of the purchase price
described in Section 2 have been satisfied, Phage International shall deliver a stock certificate representing the Phage International Shares to Purchaser. Purchaser consents to the placement of a
restrictive legend on the certificate representing the Phage International Shares in the following form: 

THESE
SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE APPLICABLE
STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE MADE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD
OF TIME. 

    6.  Mutual Release of Claims.  Except for obligations set forth in this Agreement, Phage International
and Vendor each release and forever discharge the other and the other's officers, directors, shareholders, employees, representatives, and agents from any and all causes of action, claims, damages,
liabilities, and demands of any nature whatsoever relating to or arising out of the Initial Transaction, Vendor's purchase and Phage International's issuance of the Phage International Shares, and the
delay in the originally-anticipated closing of the Initial Transaction. 

    7.  Miscellaneous.  

    7.1 Vendor
shall not transfer or assign this Agreement or any of its rights under this Agreement without the consent of Phage International and Purchaser. Subject to
the foregoing, this Agreement shall be binding upon and inure to the benefit of the parties and their respective heirs, executors, administrators, successors and assigns. 

    7.2 Notwithstanding
any provision of the Purchase Agreement, the Purchase Agreement and this Agreement shall be governed by and construed in accordance with the laws of
the State of Washington. Any dispute regarding the interpretation or enforcement of the Purchase Agreement or this Agreement shall be resolved by binding arbitration in Seattle, Washington. The
prevailing party in such a dispute shall be entitled to recover its reasonable attorneys' fees and costs. 

    7.3 The
parties shall execute and deliver such other instruments and take such other actions as may be required to confer to the parties and their respective assignees
the benefits contemplated by this Agreement. 

3

 

    7.4 This Agreement may be executed in one or more counterparts, each of which shall be deemed an original of this Agreement and all of which, when taken together, will
be deemed to constitute one and the same agreement. EXECUTED as of the date first above written. 

	 	 	PHAGE THERAPEUTICS INTERNATIONAL, INC.
	

 	
 	

By	

  

	 	 	 	Its	  

	

 	
 	

VENDOR
	

 	
 	

By	

  

	 	 	 	Its	  

	

 	
 	

PURCHASER
	

 	
 	

By	

  

	 	 	 	Its	  

4

QuickLinks

STOCK PURCHASE AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00032-of-00352.parquet"}]]